Olanzapine With or Without Fosaprepitant for Preventing Chemotherapy Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy: A Phase III Randomized, Double-Blind, Placebo-Controlled Trial (ALLIANCE A221602)

PURPOSE: A protocol was developed to evaluate the value of an NK-1 receptor antagonist for preventing nausea and vomiting resulting from highly emetogenic chemotherapy when an olanzapine-based antiemetogenic regimen was used. MATERIALS AND METHODS: A221602, a prospective double-blind, placebo-contro...

Descripción completa

Detalles Bibliográficos
Autores principales: Navari, Rudolph M, Le-Rademacher, Jennifer, Smieliauskas, Fabrice, Ruddy, Kathryn J, James Saphner, Thomas, Liu, Heshan, Harlos, Elizabeth, Onitilo, Adedayo A, Giridhar, Karthik, Paul Singh, Preet, Reddy, Pavan S, Chow, Selina, Kruter, Flavio, Raptis, George, Loprinzi, Charles L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Symptom Management and Supportive Care
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10400142/
https://www.ncbi.nlm.nih.gov/pubmed/37284847
http://dx.doi.org/10.1093/oncolo/oyad140

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10400142/
https://www.ncbi.nlm.nih.gov/pubmed/37284847
http://dx.doi.org/10.1093/oncolo/oyad140

Ejemplares similares